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The aim of this study was to use indicators to evaluate physician adherence to prescription guidelines 
for heart failure treatment in a university hospital. This was a prospective cohort study conducted in a 
university hospital. The information collected at the time of patient admission, including therapeutic 
indication, absolute contra indications and intolerance, was utilised for the formulation of a guideline 
adherence indicator (GAI). This indicator was calculated as follows: (the number of patients who used 
the medication/the number of eligible patients) x 100. The percentage of eligible patients was calculated 
using the following formula: (the number of eligible patients/the total number patients) x 100. The GAI 
was applied to a population of 53 patients. Inhibitors of angiotensin-converting enzyme/angiotensin 
receptor blocker (ACE-I/ARB) combination therapy were used in the greatest percentage of eligible 
patients (92.4%) and demonstrated the largest GAI value (73.5%). The percentages of patients who 
were eligible for beta-blockers, spironolactone and digitalis treatments were 81.1%, 52.8% and 60.4%, 
respectively. The GAI values for the use of beta-blockers, spironolactone and digitalis were 60.4%, 57.1% 
and 56.2%, respectively. For the studied patient population, the GAI was consistent with the proportion 
of patients who were eligible to receive digitalis and spironolactone.
Uniterms: Heart failure/treatment. Health care. Clinical medicine/practice guidelines. Medicines/use. 
Medicines/prescriptions.
O objetivo deste estudo foi utilizar indicadores para avaliar a adesão de médicos às diretrizes para 
tratamento da Insuficiência Cardíaca em um hospital universitário. Estudo de coorte prospectivo, 
conduzido em um hospital universitário. As variáveis coletadas na admissão do paciente foram: indicação 
terapêutica, contraindicações absolutas e intolerância, sendo utilizadas para elaboração de um indicador 
de adesão à diretriz (IAD). Este indicador foi calculado através da relação: (número de pacientes que 
utilizaram o medicamento/número de pacientes elegíveis) x 100. A % de pacientes elegíveis foi calculada 
da seguinte forma: (número de pacientes elegíveis/número total de pacientes) x 100. Os IAD foram 
aplicados para uma população de 53 pacientes. Os Inibidores da Enzima Conversora de Angiotensina/
Bloqueadores dos Receptores de Angiotensina foram as classes farmacológicas que apresentaram maior 
% de pacientes elegíveis (92,4%) e apresentaram o melhor IAD (73,5%). A % de pacientes elegíveis para 
beta-bloqueadores, espironolactona e digitálicos foi de 81,1%, 52,8% e 60,4%, respectivamente. O IAD 
para beta-bloqueadores foi 60,4%, espironolactona 57,1% e digitálicos 56,2%. Na população estudada, 
o IAD foi compatível com a proporção de pacientes elegíveis para digitálicos e espironolactona.
Unitermos: Insuficiência cardíaca. Assistência à Saúde. Clinica médica/guia prático. Medicamentos/
uso. Medicamentos/prescrição.
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INTRODUCTION
Heart failure (HF) is a major health problem 
associated with high levels of morbidity and mortality 
(Komajda et al., 2003). Furthermore, it is estimated 
that 30% of patients are re-hospitalised within the first 
year of diagnosis and that the 5-year mortality rate may 
be greater than 50% (Ho et al., 1993). The therapeutic 
objectives for the treatment of HF are focused on 
improving the patient’s quality of life, alleviating or 
reducing symptoms, preventing hospitalisation, slowing 
the progression of the illness and increasing the survival 
rate. The use of angiotensin-converting enzyme inhibitors 
(ACE-Is), angiotensin receptor blockers (ARBs) and 
beta-blockers (BBs) has shown a reduction in the 
mortality and hospital admission rates for patients with 
HF, and the greatest benefit of these therapies has been 
for patients with severe HF (Bocchi et al., 2009). Based 
on these findings, various professional associations have 
developed guidelines for the assessment and treatment of 
HF (Bocchi et al., 2009). In Brazil, the Brazilian Society 
of Cardiology (BSC) published a set of guidelines in 
2009 (Bocchi et al., 2009).
Certain international organisations suggest the use 
of quality indicators for the treatment of HF because 
multiple studies have shown that published guidelines are 
commonly not followed, especially regarding medication 
selection and the dosage used (Drechsler et al., 2005). 
In addition to the underutilisation of recommended 
medications, polypharmacy often occurs in the treatment 
of HF. Moreover, the difficulty of accessing data from 
recent clinical trials may further hinder physicians’ 
ability to manage HF treatment (Komajda et al., 
2003). Additionally, studies have shown that physician 
adherence to prescription guidelines for HF treatment 
has improved the prognosis for related pathologies 
(Komajda et al., 2003). According to the results of 
the MAHLER study, good physician adherence to HF 
treatment guidelines, as assessed using indicators, was 
associated with a reduction in the 6-month hospitalisation 
rate (Komajda et al., 2003). These indicators accounted 
for criteria regarding the use of various HF medications, 
as published in the guidelines of the European Society 
of Cardiology (ESC). Subsequently, two additional 
studies uti l ised national or recently developed 
guidelines from the ESC for the development of similar 
evaluations (Peters-Klimm et al., 2007; Störk et al., 
2008).
The aim of this study was to use indicators to 
evaluate physician adherence to prescription guidelines 
for HF treatment in a university hospital.
METHODS
The Study for the Identification of Treatable Causes 
and Therapeutic Optimisation of Heart Failure (SITCO) 
is an observational study with the main objectives of 
identifying the treatable causes of decompensation and 
the need for hospitalisation due to HF and evaluating the 
frequency and appropriateness of medication use for HF 
pathology. A prospective cohort of patients hospitalised 
for HF was treated at a Brazilian university hospital. The 
data were collected during patient admission and stay at 
the hospital using a standard survey, an interview and the 
review of medical records. The data sources included the 
prescriptions prior to hospitalisation and the diagnoses 
during the patient’s stay at the hospital during the period 
from July 2009 to December 2010. The SITCO included 
patients with decompensated HF but excluded those with 
untreatable concomitant disease and an estimated life 
expectancy of less than one year.
A version of the guidelines that were developed 
by the MAHLER study was used to calculate the 
guideline adherence indicator (GAI) (Komajda et 
al., 2005). The criteria regarding contraindications 
established in this study were adapted for a Brazilian 
context, and these criteria were in agreement with the 
medication criteria established by the III Brazilian 
Guidelines for Chronic Heart Failure (Komajda et al., 
2005). The GAI that was used considered the indications 
for each drug, the absolute contraindications, the 
intolerance indications and other clinical situations 
that would require greater precautions to be made for 
the clinical management of patients. Criteria for drug 
use (indications and contraindications) were extracted 
for each pharmacological group, including the ACE-I, 
ARB, aldosterone antagonist and BB treatments, based 
upon information in the Brazilian guidelines (Bocchi 
et al., 2009). The data were transformed into eligibility 
criteria for treatment with a given medication, which 
were then compared to the clinical data and the data 
regarding treatment at the time of hospital admission 
(Table I). Patients eligible for treatment for heart 
failure were those with indications for each drug, no 
absolute contraindications, intolerance or other medical 
conditions which require greater precautions in clinical 
management.
The term adherence in this study refers only to 
the comparison of the prescribed treatment within the 
guideline recommendations. The percentage of eligible 
patients was calculated in the following manner: (the 
number of eligible patients/the total number of patients) 
x 100. The GAI was calculated based on the following 
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TABLE I - The general eligibility criteria for HF treatment according to therapeutic class and based on the national guidelines
Therapeutic class National guideline recommendations Contraindications
ACE-I or ARB EF ≤40% independent of symptoms
Bilateral renal artery stenosis, K+ >5.0 mmol/L, 
Cr >2.5 mg/dL, serious aortic stenosis, symptomatic 
hypotension,  cough, pregnancy/breastfeeding, 
hypersensibility, cardiogenic shock 
Beta-blockers*
LVEF <40% and HF II-IV, asymptomatic 
after MI with dysfunction of LV, clinical 
stability 
Asthma, serious COPD, bradycardia <5, Second- and 
third-degree AV block, sinus node disease, symptomatic 
hypotension, hemodynamic repercussion with valvular 
disease, cardiogenic shock, life expectancy less than one 
year, liver failure, decompensated HF, hypersensibility. 
Aldosterone antagonists LVEF  <35%, HF III - IV,  BB and optimised ACEI/ARB 
K+ >5.0 mmol/L, Cr >2.5 mg/dL, use of ACE-I+ARB, 
hypersensibility.
Digitalis
AF with RV >80 bpm, sinus rhythm with 
symptoms (HF II-IV), optimised dose of 
ACE-I/ARB, BB and spironolactone.
Second- and third-degree AV block, pre-excitation, 
symptomatic bradycardia without pacemaker, intolerance 
to digitalis.
*Except for metoprolol tartrate, propranolol and atenolol; LVEF - left ventricular ejection fraction; AF - atrial fibrillation; BB - 
beta-blocker; COPD - Chronic Obstructive Pulmonary Disease; MI - Myocardial infarction.
ratio: (the number of patients who used the medication/
the number of eligible patients) x 100. Deaths were 
excluded from both calculations, because for these patients 
was not possible to investigate all the possibilities of 
contraindications or intolerance or even confirmation 
of indication for each drug. Therefore, these patients 
died before a complete clinical investigation. For each 
therapeutic class that was recommended in the clinical 
guidelines, there was one corresponding GAI that could 
vary between 0 and 100%. Because evidence for the 
benefits would be stronger for the use of ACE-I, BBs 
or spironolactone than for digitalis, a separate GAI was 
calculated based upon the set of these three classes (GAI-
3) (Komajda et al., 2005).
The GAIs for pharmacological class and the GAI-3 
were calculated based on the data collected during the 
patients’ hospital stays as well as the SITCO baseline 
data from 2010. The variables of interest included 
demographic data, the functional class according to 
NYHA, various laboratory data, co-morbidities (such as 
atrial fibrillation, coronary disease, hypertension, asthma, 
chronic obstructive pulmonary disease and renal failure) 
and the HF medications used (including BBs, ACE-I or 
ARB, digoxin and spironolactone).
The results were analysed using SPSS 11.0 software 
and are shown as the mean ± standard deviation for 
continuous variables or as frequencies for dichotomous 
variables. All data referring to the medications administered 
were stratified according to pharmacological class. 
The SITCO was approved by the local ethics research 
committee.
RESULTS AND DISCUSSION
The GAI was applied to a population of 53 patients. 
The most common aetiology for HF was Chagas disease 
(37.7%). The majority of patients (80.3%) had been given 
a previous diagnosis of HF prior to their admission to the 
hospital, and 44.3% of these patients had been admitted 
with serious ventricular dysfunction (Table II).
The most commonly prescribed pharmacological 
drug classes upon admission were the ACE-I and ARB 
medications (68.8%), which demonstrated the best GAI 
values (73.5%). However, the combination of these 
medications with either BBs or spironolactone led to a 
GAI of 40.7% (Table III).
We found a GAI of 40.7% for the combination of 
ACE-I/ARB, BBs and spironolactone. For the individual 
pharmacological classes, the GAI varied from 52% to 
73.5%.
The frequency of patients who receive ACE-I or 
BBs at the routine and appropriate doses is regarded as 
a quality indicator for HF treatment (Pereira Barretto et 
al., 2001). Since 1997, the routine use of ACE-I/ARB has 
been recommended for the management of HF cases due 
to left systolic ventricular dysfunction (Komajda et al., 
2003; Drechsler et al., 2005). The combined use of these 
medications with diuretics has resulted in patients being 
less symptomatic with lower degrees of decompensation, 
less hospitalisation and lower mortality rates from this 
disease (Pereira Barretto et al., 2001). Studies have also 
shown a decrease in mortality among patients who have 
left ventricular dysfunction and have been treated with 
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aldosterone antagonists (Pereira Barretto et al., 2001). 
The DIG study revealed that hospitalisation due to 
worsening of the disease decreased by 28% in the group 
that was treated with digoxin (The effect of digoxin on 
mortality and morbidity in patients with HF. The Digitalis 
Investigation Group, 1997).
The GAI was also used in three previous European 
studies that assessed the quality of care in patients with HF 
(Störk et al., 2008). However, only two of these studies 
considered contraindications and patient intolerance when 
establishing the eligibility criteria for HF treatment (Störk 
et al., 2008). The first study reported that after adjusting 
for potential contradictions (COPD, heart rate <60/min, 
hypotension, hyperkalaemia and renal dysfunction), 
adherence appeared to be 49% for ACE-I/ARB treatments 
and 46% for BB treatments. Aldosterone antagonists were 
prescribed for 57% of cases, whereas the prescription rate 
for triple therapy (ACE-I/ARB + BB + AA) was only 25% 
for 83 indicated cases (Peters-Klimm et al., 2007). The 
second study reported that the median GAI-3 was 67% for 
patients with a reduced LVEF (Störk et al., 2008).
The current study used an identical methodology and 
adapted these criteria for use with the Brazilian guidelines. 
Numerous studies have described only the prescription 
frequencies of these medications without considering 
the possible contraindications or intolerances (Boyles et 
al., 2004; Adams et al., 2005; Jaarsma, et al., 2005). As a 
result, this approach may have led to a misinterpretation 
of the quality of care provided, given that each of these 
studies indicated the underutilisation of medications that 
have been proven to be beneficial in large clinical trials 
and have been disclosed in national and international 
guidelines.
In  Brazi l ,  few s tudies  have evaluated the 
appropriateness of medication prescriptions for patients 
with HF or demonstrated the underutilisation of BBs and 
ACE-I treatments at lower than the recommended doses 
(Pereira Barretto et al., 2001). In a Brazilian survey, 
a questionnaire was used to compare the perceptions 
regarding diagnosis with the management of HF among 
clinical cardiologists and family physicians. The doses of 
ACE-I medications that were issued by the cardiologists 
were greater than the doses issued by family physicians, 
although the doses of spironolactone were closer to those 
TABLE II - Patient characteristics (N = 61)
Characteristics
Age (M ± SD) 57.1 ± 14.3
Male n (%) 34 (55.7)
Aetiology n (%)
         Chagas
         Idiopathic
         Ischemic
         Hypertensive
         Valvular







Previous diagnosis of HF n (%) 49 (80.3)
Serious ventricular dysfunction 
(LVEF <30%) n (%)
27 (44.3)
Duration of hospital stay in days (M±SD) 23.1±19
Admitted to ICU n (%) 24 (39.3)
Use of vasoactive drugs n (%) 19 (31.1)
Comorbidities n (%)
         Hypertension
         Diabetes
         Asthma







HF - Heart failure; LVEF - Left ventricular ejection failure; ICU 
- Intensive Care Unit; COPD - Chronic Obstructive Pulmonary 
Disease.
TABLE III - Proportion of patients with medications for HF at the time of admission, eligible patients and the GAI for each 
pharmacological group
Therapeutic class
Per cent of patients with 
prescription at admission 
(n/N)




ACE-I/BRA 68.8 (42/61) 92.4 (49/53) 73.5 [36/49]
BB 54.1 (33/61) 81.1 (43/53) 60.4 [26/43]
Spironolactone 49.2 (30/61) 52.8 (28/53) 57.1 [16/28]
Digitalis 44.3 (27/61) 60.4 (32/53) 56.2 [18/32]
Diuretics 67.2 (41/61) - -
(ACEI/ARB)+BB+ Spironolactone 32.8 (20/61) 50.9 (27/53) 40.7 [11/27]*
*GAI-3. ACE-I - angiotensin-converting enzyme inhibitors; BB - beta-blocker; ARB - angiotensin receptor blocker
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recommended in the literature (Pereira Barretto et al., 
2001). In another Brazilian study, the underutilisation 
of ACE-Is (64.1%) and BBs (41.1%) was demonstrated 
in primary care patients. The most commonly used 
BBs included propranolol and atenolol, which have not 
been shown to provide benefits for patients with HF 
(Moscavitch et al., 2009). These studies were based 
upon data from the guidelines of the BSC for assessing 
prescriptions and were limited to describing the frequency 
of use of pharmacological agents.
In the current study, approximately 20% of the 
patients evaluated had not been given a previous 
diagnosis of HF, and this fact may have contributed to 
the underutilisation of medication in these patients. For 
the ACE-I/ARB medications and BBs, the proportion 
of eligible patients was greater than 80% for each 
class (92.4% and 81.1%, respectively). However, only 
the appropriateness of use regarding the ACE-I/ARB 
medications surpassed data from previous studies.
The number of patients with a LVEF <30%, the 
severity of the cases requiring admission to the ICU and 
the use of vasoactive drugs suggest that specific groups 
of patients may not be able to tolerate the use of BBs, 
which were the pharmacological class with the lowest 
GAI in the studied population. The respective GAIs for 
spironolactone and digoxin were similar to the proportion 
of eligible patients. The combined use of ACE-I/ARB 
medications with BBs and spironolactone also had a GAI 
that was similar to the proportion of eligible patients. 
These results support the hypothesis that a simple 
description regarding the existing data on medication use 
for patients with HF that does not account for the clinical 
aspects of treatment could yield false evidence for the 
underutilisation of these medications.
The present study provided an opportunity 
for clinical practitioners who are not affiliated with 
a teaching hospital to communicate with general 
practitioners who attend to patients with HF in the 
community, regardless of their specialty. Because these 
data originated from hospital admissions, additional 
medications could have been introduced later during the 
hospital stay. However, analysis of the data from SITCO 
during the patients’ stay at the hospital would permit us 
to evaluate whether the therapy was optimised during the 
period of hospitalisation.
The SITCO study includes a population of heart 
failure patients hospitalized in the study institution. 
No sample was taken. As it comes to hospitalization of 
patients with HF in a specialized unit, the authors believe 
that the data presented are useful for clinical practice, 
although not a random sample. Even if it was a random 
sample, statistical inference would come down to the 
institution of study.
The methodology for the use of the GAI may be 
useful for assessing with greater accuracy whether there is 
underutilisation of certain therapeutic classes of drugs for 
the treatment of HF, given that certain contraindications 
are very common in patients with COPD, kidney disease, 
hyperkalaemia and other conditions. Therefore, the GAI 
approach should be preferentially used for studies with 
institutional data involving thousands of patients.
Using the criteria related to medication use that 
are based on national guidelines and applying the GAI 
approach to a population of hospitalised patients with 
HF revealed that this strategy could accurately define 
standards for the quality of care of these patients. This 
strategy also accounts for the eligibility regarding the 
use of each specific treatment. The use of the GAI for 
patients with HF was shown to be an easily applied tool 
that is capable of aiding the monitoring of care in both 
outpatient and hospitalised patients. Furthermore, in the 
studied population, the GAI for each selected medication 
was not consistent with the proportion of patients who 
were eligible for treatment with BBs and ACE-I/ARB 
medications.
REFERENCES
ADAMS, K.F.; FONAROW, G.C.; EMERMAN, C.L.; 
LEJEMTEL, T.H.; COSTANZO, M.R.; ABRAHAM, 
W.T.; BERKOWITZ, R.L.; HORTON, D.P. Characteristics 
and outcomes of patients hospitalized for heart failure 
in the United States: rationale, design, and preliminary 
observations from the first 100,000 cases in the Acute 
Decompensated Heart Failure National Registry 
(ADHERE). Am. Heart J., v.149, n.2, p.209-216, 2005.
BOCCHI, E.A.; MARCONDES-BRAGA, F.G.; AYUB-
FERREIRA, S.M.; ROHDE, L.E.; OLIVEIRA, W.A.; 
ALMEIDA, D.R. Sociedade Brasileira de Cardiologia. III 
diretriz brasileira de insuficiência cardíaca crônica. Arq. 
Bras. Cardiol., v.93, suppl.1, 71 p., 2009.
BOYLES, P.J.; PETERSON, G.M.; BLEASEL, M.D.; VIAL, 
J.H. Undertreatment of congestive heart failure in an 
Australian setting. J. Clin. Pharm. Ther., v.29, n.1, p.15-
22, 2004.
DRECHSLER, K.; DIETZ, R.; KLEIN, H.; WOLLERT, K.C.; 
STORP, D.; MOLLING, J.; ZEYMER, U.; NIEBAUER, J. 
Euro heart failure survey. Medical treatment not in line with 
current guidelines. Z. Kardiol., v.94, n.8, p.510-515, 2005.
M. G. Oliveira, L. C. Passos, E. G. Santos Júnior, A. C. Barbosa, D. B. Santos836
HO, K.K.; PINSKY, J.L.; KANNEL, W.B.; LEVY, D. The 
epidemiology of heart failure: the framingham study. J. Am. 
Coll. Cardiol., v.22, n.4, suppl.A, p.6A-13A, 1993.
JAARSMA, T.; HAAIJER-RUSKAMPB, F.M.; HEIDRUN, 
S.; VAN VELDHUISEN, D.J. Management of heart failure 
in the netherlands. Eur. J. Heart Fail, v.7, n.3, p.371-375, 
2005.
KOMAJDA, M.; FOLLATH, F.; SWEDBERG, K.; CLELAND, 
J.; AGUILAR, J.C.; COHEN-SOLAL, A.; DIETZ, 
R.; GAVAZZI, A.; VAN GILST, W.H.; HOBBS, R.; 
KOREWICKI, J.; MADEIRA, H.C.; MOISEYEV, V.S.; 
PREDAN, I.; WIDIMSKY, J.; FREEMANTLE, N.; 
EASTAUGH, J.; MASON, J. The EuroHeart Failure Survey 
programme--a survey on the quality of care among patients 
with heart failure in Europe. Part 2: treatment. Eur. Heart 
J., v.24, n.5, p.464-474, 2003.
KOMAJDA,  M. ;  LAPUERTA,  P. ;  HERMANS,  N. ; 
GONZALEZ-JUANATEY, J.R.; VAN VELDHUISEN, 
D.J.; ERDMANN, E.; TAVAZZI, L. POOLE-WILSON, 
P.; LE PEN, C. Adherence to guidelines is a predictor of 
outcome in chronic heart failure: the MAHLER survey. Eur. 
Heart J., v.26, n.16, p.1653-1659, 2005.
MOSCAVITCH, S.; GARCIA, J.L.; ROSA, L.F.; PESTANA, 
P.R.; MORAES, L.V.; SILVA, C.M.; MOUTINHO, M.A.; 
COELHO, F.A.; ROSA, M.L.; MESQUITA, E.T. Are heart 
failure guidelines being implemented in primary care? Rev. 
Port. Cardiol., v.28, n.6, p.683-696, 2009.
PEREIRA BARRETTO, A.; NOBRE, M.C.; LANCAROTTE, 
I.; SCIPIONI, A.R.; RAMIRES, J.A. Do cardiologists at a 
university hospital adopt the guidelines for the treatment of 
heart failure? Arq. Bras. Cardiol., v.77, n.1, p.30-36, 2001.
PETERS-KLIMM, F.; MULLER-TASCCH, T.; SCHELLBER, 
D.; REMPPIS, A.; BARTH, A.; HOLZAPFEL, N.; 
JÜNGER, J.; HERZOG, W.; SZECSENYI, J. Guideline 
adherence for pharmacotherapy of chronic systolic heart 
failure in general practice: a closer look at evidence-based 
therapy. Clin. Res. Cardiol., v.97, n.4, p.244-252, 2007.
STÖRK, S.; HENSE, H.W.; ZENTGRAF, C.; UEBELACKER, 
I . ;  JAHNS, R.;  ERTL, G.;  ANGERMANN, C.E. 
Pharmacotherapy according to treatment guidelines is 
associated with lower mortality in a community-based 
sample of patients with chronic heart failure: a prospective 
cohort study. Eur. J. Heart Fail., v.10, n.12, p.1236-1245, 
2008.
THE DIGITALIS INVESTIGATION GROUP. The effect of 
digoxin on mortality and morbidity in patients with heart 
failure. N. Engl. J. Med., v.336, n.8, p.525-533, 1997.
Received for publication on 20th December 2012
Accepted for publication on 22nd August 2013
